Guideline for the management of acute asthma in children: 2013 update by Kling, S et al.
South African Medical Journal
March 2013, Vol. 102, No. 3
 Guideline for the management of acute 





























Professional Advertising  
Lisa Reid 












Sales Director: Diane Smith 
Tel. (012) 481-2069
Email: dianes@samedical.org
HMPG Board of Directors 




J P de V van Niekerk
Associate Editors 











March 2013, Volume 103, No. 3








 3.1 Pulse oximetry
 3.2 Chest X-ray (CXR)
 3.3 Arterial blood gas (ABG)
202 4. Initial and first-line management of acute asthma
 4.1 Oxygen
 4.2 Short-acting beta-2 (β2)-agonist bronchodilators
 4.3 Steroid therapy
 4.4 Ipratropium bromide
203 5. Additional therapy for acute asthma
 5.1 Intravenous low-dose bolus salbutamol
 5.2 Intravenous salbutamol by continuous infusion
 5.3 Intravenous aminophylline
 5.4 Magnesium sulphate
 5.5 Adrenaline
 5.6 Inhaled steroids (ICS)
 5.7 Rapid-onset long-acting β2-agonists (formoterol)
 5.8 Leukotriene receptor antagonists
 5.9 Antibiotics
 5.10 Heliox
 5.11 Intravenous fluids
204 6. Indications for hospitalisation
204 7. Indications for  PICU admission
 7.1 Treatment of acute severe asthma in ICU
205  8. Acute asthma in very young children
 8.1 Treatment of acute asthma in children aged <2 years
205 9. Hospital discharge and follow-up
206 References
207 Management of acute severe asthma in children
207 Drug doses for acute asthma
GUIDELINES
200  March 2013, Vol. 103, No. 3  SAMJ
Asthma is the most common chronic disease of childhood. Acute 
asthma exacerbations cause considerable morbidity and health cost 
utilisation, as well as substantial mortality. Asthma exacerbations 
are an indication of loss of asthma control and should prompt 
re-evaluation of the child’s illness and the use of controller 
therapy. The last South African paediatric acute asthma guidelines were 
published in 1993.[1] The current revision was prompted by the following:
• subsequent publication of several studies of different management 
strategies for acute asthma
• changes in international guidelines
• updated recommendations for the recognition and assessment of 
acute severe asthma
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Background. Acute asthma exacerbations remain a common cause of hospitalisation and healthcare utilisation in South African children.
Aim. To update the South African paediatric acute asthma guidelines according to current evidence, and produce separate recommendations 
for children above and below 2 years of age.
Methods. A working group of the South African Childhood Asthma Group was established to review the published literature on acute 
asthma in children from 2000 to 2012, and to revise the South African guidelines accordingly.
Recommendations. Short-acting inhaled bronchodilators remain the first-line treatment of acute asthma. A metered dose inhaler with 
spacer is preferable to nebulisation for bronchodilator therapy to treat mild to moderate asthma. Two to four puffs of a short-acting 
bronchodilator given every 20 - 30 minutes, depending on clinical response, should be given for mild attacks; up to 10 puffs may be 
needed for more severe asthma. Children with severe asthma or oxygen saturation (SpO2) <92% should receive oxygen and frequent 
doses of nebulised β2-agonists, and be referred to hospital. Nebulised ipratropium bromide (via nebulisation or multidosing via pMDI-
spacer combination) should be added if there is a poor response to three doses of β2-agonist or if the symptoms are severe. Early use of 
corticosteroids reduces the need for hospital admission and prevents relapse; oral therapy is preferable. Assessment of acute asthma in 
children below the age of 2 years can be difficult, and other causes of wheezing must be excluded. Treatment of acute asthma in this age 
group is similar to that of older children.
Conclusion. Effective therapy for treatment of acute asthma – primarily inhaled short-acting β2-agonists, oral corticosteroids and oxygen 
with appropriate delivery systems – should be available in all healthcare facilities and rapidly instituted for treatment of acute asthma in 
children.
Endorsement. The guideline document is endorsed by the Allergy Society of South Africa (ALLSA), the South African Thoracic Society 
(SATS), the National Asthma Education Programme (NAEP), the South African Paediatric Association (SAPA) and the South African 
Academy of Family Practice.
S Afr Med J 2013;103(3):199-207. DOI:10.7196/SAMJ.6658
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• increasing recognition of the importance of preschool wheezing, 
and the need for different treatment strategies in very young 
compared with older children
• the development of new formulations and asthma drugs.
1. Methodology
The acute asthma working group guideline was developed as part of 
the South African Childhood Asthma Working Group (SACAWG) 
guideline, with the chronic management guideline published in 
2009. [2] A Pubmed literature search was performed for English 
language publications on treatment of acute asthma in children, from 
2000 to 2012 inclusive. The search strategy used the following terms: 
‘asthma’ and ‘child’ and ‘treatment’, and ‘acute asthma attack’ and 
‘status asthmaticus’. 
Although many of the drugs used in the treatment of acute asthma 
in children are used off-label, the recommendations are based on the 
best available evidence and the drugs are in common use.
1.1 Levels of evidence
The strategies recommended in this guideline are classified according 
to the evidence categories in Table 1 and denoted as evidence A, B, C 
or D.
1.2 Definitions
Acute asthma is characterised by a progressive increase in shortness 
of breath, cough, wheeze or tight chest that does not respond to the 
patient’s usual bronchodilator therapy.
Mild asthma exacerbations are just outside the normal range of 
variation for an individual patient and are difficult to distinguish 
from transient loss of asthma control.[4]
Moderate asthma exacerbations are defined as at least one of the 
following occurring for at least 2 days without the need for systemic 
corticosteroids (CS): increasing asthma symptoms, worsening lung 
function, and/or increased rescue bronchodilator use.[4] Emergency 
department (ED) visits not requiring CS are classified as moderate 
disease exacerbations.
Severe asthma exacerbations necessitate urgent action by the 
patient/parent and doctor to prevent a serious outcome, such as 
hospitalisation or death. The definition requires either an asthma-
related hospitalisation or a visit to the ED or an urgent care facility, 
together with treatment with systemic CS for at least 3 days.[4] The 
features of a severe asthma exacerbation are: inability to complete 
sentences in one breath and/or too breathless to talk or feed; use of 
accessory muscles of respiration; tachycardia; tachypnoea; agitation; 
oxygen saturations (SpO2) <92%; peak expiratory flow rate (PEFR) 
33 - 50% best or predicted.[3]
Acute severe asthma, formerly known as status asthmaticus, is 
defined as severe asthma unresponsive to repeated courses of ß2 
agonist therapy. It is a medical emergency that requires immediate 
recognition and treatment. 
Near-fatal asthma is acute severe asthma associated with a 
respiratory arrest or hypercarbia.[5]
2. Assessment
The management of acute asthma depends on the assessment of 
severity. The initial quick assessment should determine whether the 
child shows any risk factors for (Table 2) or symptoms or signs of 
life-threatening asthma (Table 3).[3,6] The PEFR can usually only be 
measured in children older than 6 years, and who are accustomed to 
having their PEF measured.
Before children can receive appropriate treatment for acute 
asthma, the severity of their symptoms must be assessed accurately. 
The following clinical signs should be recorded:
• pulse rate
• respiratory rate and degree of breathlessness (ability to complete 
sentences in one breath or to feed)
• use of accessory muscles of respiration
• amount of wheezing (how audible it is)
• degree of agitation and level of consciousness.
Increasing tachycardia generally denotes worsening asthma, 
whereas a fall in heart rate in life-threatening asthma is a pre-terminal 
Abbreviations





PaCO2 Partial pressure of carbon dioxide in arterial blood
PaO2 Partial pressure of oxygen in arterial blood
PEF Peak expiratory flow
PEFR Peak expiratory flow rate
PICU Paediatric intensive care unit
pMDI Pressurised metered dose inhaler
SACAWG South African Childhood Asthma Working Group
SpO2 Oxygen saturation (measured peripherally by pulse 
oximetry)
Table 1. Categories of evidence for management strategies 
in asthma (reproduced from Global Initiative for Asthma - 
2009[3])
Evidence 
category Sources of evidence 
A Randomised controlled trials: Rich body of data 
B Randomised controlled trials: Limited body of data 
C Non-randomised trials: Observational studies
D Panel consensus judgement 
Table 2. Risk factors for potentially fatal asthma in children 
(adapted from Global Initiative for Asthma,[3] British Thoracic 
Society/Scottish Intercollegiate Guidelines Network[6])
Previous near-fatal asthma
Previous admission to a PICU for asthma
Admission for asthma in the last year
Excessive use of or overdependence on ß2 agonists
Current use or recent use of oral corticosteroids
Repeated attendances at emergency unit for asthma treatment, 
especially if in the last year
‘Brittle’ asthma (sudden onset of acute severe asthma attacks)
Poor adherence to medication
Psychosocial and/or family problems
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event. Although wheezing initially becomes more apparent as airway 
obstruction increases, severe airway obstruction decreases air flow, 
with wheezing becoming softer and then diminishing completely 
(silent chest).
It is important to realise that clinical signs correlate poorly with the 
severity of airways obstruction.[6-10] Some children may have very severe 
airways obstruction without appearing to be obviously distressed.
3. Investigations
3.1 Pulse oximetry
Oxygen saturation monitors should be available at all facilities that 
treat children with acute asthma. Low arterial oxygen saturation 
in room air (SpO2 <92%) after the initial bronchodilator therapy 
suggests a more severe group of patients and is an indication for 
admission.[6-8,10] All children with SpO2 <92% in room air after initial 
bronchodilator therapy must be admitted for inpatient treatment 
and monitoring.
3.2 Chest X-ray (CXR)
Routine CXRs are unnecessary. Indications for a CXR in acute 
asthma are: 
• failure to respond to standard therapy 
• subcutaneous emphysema or chest pain, suggesting an air leak 
or pneumothorax 
• clinical signs suggesting lung collapse, consolidation or 
pneumothorax 
• life-threatening asthma not responding to maximal therapy. 
A CXR may also be indicated to rule out alternative or concomitant 
diagnoses, especially in children not responding to treatment.
3.3 Arterial blood gas (ABG)
Indications for doing an ABG include severe or life-threatening 
asthma not responding to treatment. The PaCO2 is low in the early 
stages of acute asthma as a compensatory mechanism. A normal or 
raised PaCO2 indicates worsening asthma and respiratory failure.
4. Initial and first-line management of 
acute asthma
The initial treatment of an acute asthma attack consists of repeated 
doses of rapidly acting inhaled β2-agonists, systemic CS, and oxygen 
if hypoxic; all these therapies are supported by existing evidence as 
indicated in the text.
4.1 Oxygen
Children with life-threatening asthma, severe asthma or oxygen 
saturations less than 92% should receive oxygen via a high-flow face 
mask or nasal cannulas to maintain normal saturations (evidence A) 
and be admitted (evidence B). There is currently no consensus as to 
whether the oxygen should be humidified.[11,12] In hospitals, nebulisers 
should preferably be oxygen-driven.
4.2 Short-acting beta-2 (β2)-agonist bronchodilators
Short-acting inhaled β2-agonists are the mainstay of therapy for acute 
asthma, and the first-line treatment (evidence A). They stimulate 
β2 receptors on airway smooth muscle, resulting in smooth muscle 
relaxation.[13] However, receptors are also found in the heart, blood 
vessels, skeletal muscle, liver, pancreas and uterus, accounting for 
some of the side effects of β2-agonists including tachycardia, tremor, 
hypokalaemia and hyperglycaemia. The most commonly used agents 
in South Africa are salbutamol and fenoterol; salbutamol is the 
β2 agonist of choice in the majority of international acute asthma 
guidelines.[3,6]
Inhaled β2-agonists are preferably delivered by pressurised metered 
dose inhaler (pMDI) with a spacer (2 - 10 puffs, each inhaled 
separately with five tidal breaths at 15 - 30-second intervals) or 
by oxygen-driven nebuliser (evidence A).[14] A pMDI plus spacer 
Table 3. Assessment of severity of acute asthma (adapted from Global Initiative for Asthma,[3] British Thoracic Society/Scottish 
Intercollegiate Guidelines Network[6])
Clinical signs Measurements
Life-threatening asthma Silent chest SpO2 <92%
Cyanosis PEFR <33% best or predicted or unable to perform 





Bradycardia – a pre-terminal event
Severe asthma exacerbation Unable to complete sentences in one breath; too 
breathless to talk or feed
SpO2 <92%
Agitation PEFR 33 - 50% best or predicted or unable to 
perform PEFR measurements due to fatigue
Accessory muscle use during expiration
Tachycardia*
Tachypnoea†
Moderate asthma exacerbation Able to talk in sentences
Pulse rate within normal limits
Respiratory rate within normal limits
SpO2 ≥92%
PEFR ≥50% best or predicted
*Tachycardia – heart rate >160 beats/min in children aged <1 year; >140 beats/min in children 1 - 5 years; >130 beats/min in children >5 years.
†Tachypnoea – respiratory rate >50 breaths/min in children aged <1 year; >40 breaths/min in children 1 - 5 years; >30 breaths/min in children >5 years.
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is the preferred drug-delivery device for the treatment of mild to 
moderate acute asthma, while oxygen-driven nebulisers are preferred 
for severe or life-threatening acute asthma (evidence A). In young 
children (<3 years old), a spacer with a mask should be used; in older 
children, a pMDI and spacer with mouthpiece is preferable. Home-
made spacers are as effective as commercial spacers in the treatment 
of acute asthma.[15,16] If using a pMDI and spacer with a mask, ensure 
that the mask fits closely onto the child’s face.
Frequent doses of β2-agonists are safe for the treatment of acute 
asthma (evidence A). Two to four puffs repeated every 20 - 30 
minutes depending on clinical response should be given for mild 
attacks; up to 10 puffs may be needed for more severe asthma. 
Bronchodilator therapy should be individualised depending on 
the severity of the acute asthma and the response to treatment. 
If hourly bronchodilators are required for more than 4 - 6 hours, 
the pMDI-spacer combination should be changed to a nebuliser.[6] 
Children who have not improved after receiving up to 10 puffs of 
β2-agonist should be referred to hospital. Children with severe or 
life-threatening asthma should receive nebulised β2-agonists (2.5 
- 5 mg salbutamol or 0.5 - 1 mg fenoterol) and oxygen and should 
be transferred urgently to hospital. Nebulisation with β2-agonists 
can be repeated every 20 - 30 minutes or given continuously. The 
results of studies comparing intermittent and continuous nebulised 
short-acting β2-agonists are conflicting. A recent Cochrane review 
reported that continuous nebulised β2 agonists offered a small 
advantage over intermittent nebulisation in terms of hospital 
admission and lung function, with no increase in side-effects 
(evidence A).[17]
4.3 Steroid therapy 
CS are standard first-line treatment for acute asthma, as they treat 
the underlying cause of asthma: inflammation (evidence A). They 
increase β2 receptor sensitivity by upregulating β2 expression on 
airway smooth muscle.[11,18] CS have been shown to decrease mortality, 
relapses, hospital admission and bronchodilator use. As systemic 
steroids require 6 - 24 hours to promote the anti-inflammatory 
response, early administration after presentation is necessary to 
reduce hospital admission.[12] The earlier they are administered in the 
acute attack, the better the outcome (evidence A).[19,20] Oral steroids 
are as effective as intravenous therapy, and preferable because of 
their ease of administration, cost-effectiveness and fewer side-effects.
[21-23] The recommended dose of oral prednisone or prednisolone is 
1 mg/kg/d, i.e. 20 mg in children aged 2 - 5 years and 30 - 40 mg in 
children aged >5 years.[24] Children on maintenance oral CS should 
receive 2 mg/kg/d up to a maximum dose of 60 mg.[6] A 3-day course 
is usually sufficient for children who are not hospitalised; however, 
if the asthma attack has not completely resolved then a longer 
course (7 - 14 days) may be needed.[6,25] It is unnecessary to taper the 
steroid dose unless it is used for longer than 14 days.[26,27] Intravenous 
steroids (which include hydrocortisone, methylprednisolone and 
dexamethasone), should be reserved for children with life-threatening 
asthma or those who cannot tolerate oral CS.
4.4 Ipratropium bromide
Ipratropium bromide (IB) is an anticholinergic agent that produces 
bronchodilatation within 20 - 30 minutes. Nebulised IB (250 μg/dose 
mixed with the nebulised β2-agonist solution) should be added if the 
child does not respond to three doses (nebulisation or multidosing 
via pMDI-spacer combination) of β2-agonists, or if the symptoms are 
severe (evidence A). Frequent doses of IB can be used every 20 - 30 
minutes, together with β2-agonists, for the first 2 hours of a severe asthma 
attack [6] The dose frequency should be reduced to 4 - 6-hourly as clinical 
improvement occurs. Inhaled IB may be especially useful in patients who 
have been using high doses of β2-agonists before seeking medical care. 
IB alone is a less effective bronchodilator than a β2-agonist alone, but the 
combination of nebulised IB with a nebulised β2-agonist results in greater 
bronchodilatation than a β2-agonist on its own.[28,29]
Pre-mixed combination β2-agonist and anticholinergic 
inhalant solutions should be used with caution in children, as the 
concentrations of the individual drugs are higher than recommended 
for the paediatric population (Table 4).
5. Additional therapy for acute asthma
The following therapies may be considered in the management of 
acute severe asthma not responding to standard treatment.
Administration of β2-agonists
• pMDI/spacer: start with 2 puffs of β2-agonist. Give single puffs 
one at a time; each must be inhaled separately with five tidal 
breaths at 15 - 30-second intervals. Increase β2-agonist dose by 
2 puffs every 2 minutes according to response up to 10 puffs
• A SPACER MUST be used in conjunction with a MDI in children 
of ALL ages to enable adequate delivery of bronchodilator
• doses can be repeated every 20 - 30 minutes.
• Nebuliser: 2.5 - 5 mg salbutamol or 0.5 - 1 mg fenoterol + saline 
to make nebuliser volume up to 4 ml.† Repeat at 20 - 30 -minute 
intervals
• Continuous nebulised β2-agonists: 2.5 - 5 mg salbutamol or 0.5 
- 1mg fenoterol + saline to make nebuliser volume up to 4 ml.* 
Repeat every 15 minutes until response occurs.
*The fill volume may differ depending on the nebuliser.
Administration of steroid therapy
• Prednisone or prednisolone 1 - 2 mg/kg orally (recommended 
dose 20 mg for children aged 2 - 5 years and 30 - 40 mg for 
children >5 years)
• Methylprednisolone 2 mg/kg 8-hourly IV
• Dexamethasone 0.6 mg/kg IV daily
Administration of IB
• Add 250 μg IB/dose to 2.5 - 5.0 mg of salbutamol or 0.5 - 1 mg 
fenoterol solution with saline to make a total volume of 4 ml* 
in the same nebuliser and administer every 20 - 30 minutes 
initially then 4 - 6-hourly as improvement occurs.
* The fill volume may differ depending on the nebuliser.
Table 4. Concentrations of β2-agonists and IB in 
commercially available products in SA
Product name Constituents
Adco-Combineb IB 500 μg, salbutamol 2.5 mg/2.5 ml
Adco-Nebrafen IB 500 μg, fenoterol 1.25 mg/4 ml
Combivent IB 500 μg, salbutamol 2.5 mg/2.5 ml
Duolin IB 500 μg, salbutamol 2.5 mg/2.5 ml
IB = ipratropium bromide.
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5.1 Intravenous low-dose bolus salbutamol
The use of IV low-dose salbutamol (15 μg/kg as a once-off bolus 
dose), added to standard therapy in the early management of acute 
severe asthma in children presenting to the emergency department 
(ED), may reduce the duration of the exacerbation and hasten the 
children’s discharge from hospital (evidence B).[30,31] IV salbutamol 
alone is not better than inhaled β2-agonists.[32]
5.2 Intravenous salbutamol by continuous infusion
In the paediatric intensive care unit (PICU) a high IV loading dose 
of salbutamol (5 - 10 μg/kg/min of 1 mg/ml solution infused at 
0.3 - 0.6 ml/kg/h for 1 hour ) followed by continuous infusion (1 - 
5 μg/kg/min at 0.06 - 0.3 ml/kg/h) may be effective, and is probably 
safer than aminophylline. Continuous intravenous infusion should 
be considered when there is uncertainty about reliable inhalation 
of β2-agonists or for severe refractory asthma. Electrolytes should 
be monitored regularly (evidence C).[6] Nebulised bronchodilator 
therapy should be continued while the patient is receiving IV 
salbutamol.[6]
5.3 Intravenous aminophylline
Theophylline and its water-soluble salt, aminophylline, are 
methylxanthine derivatives that have largely fallen out of favour due 
to their narrow therapeutic index and potentially severe side-effects, 
such as cardiac arrhythmias or convulsions. Neither t heophylline 
nor aminophylline is indicated in patients with mild to moderate 
acute asthma (evidence A), but may be used in cases of near-fatal 
or life-threatening asthma in the PICU (evidence C).[33-36] A 5 mg/kg 
loading dose should be given over 20 minutes under continuous ECG 
monitoring, followed by a continuous infusion at  0.5 - 1 mg/kg/h; the 
loading dose should be omitted in children receiving maintenance 
oral theophylline (evidence B).
5.4 Magnesium sulphate
Magnesium sulphate competes with calcium at smooth muscle 
binding sites, resulting in bronchodilation.[37] A single dose of 
intravenous magnesium sulphate 25 - 75 mg/kg (recommended 
dose 50 mg/kg, maximum dose 2 g) given over 20 minutes has been 
shown to be safe and effective in adults and children with acute severe 
asthma, who have had a poor response to initial therapy.[37,38] The 
response to magnesium appears to be best in patients who present 
with very severe illness (evidence C). [39-41]
The benefits associated with the use of nebulised magnesium 
sulphate remain controversial. Nebulised magnesium sulphate (0.4 
ml 50% MgSO4 added to total volume of 4 ml nebuliser volume 
to achieve an isotonic solution) added to inhaled β2-agonists in 
the treatment of an acute asthma exacerbation has been shown to 
improve lung function in patients with severe asthma, with a trend 
towards fewer hospital admissions.[42] 
5.5 Adrenaline
Intramuscular adrenaline is given for acute anaphylaxis (which may 
be confused with acute asthma) and angio-oedema, but it is not 
routinely indicated for acute asthma. Subcutaneously administered 
adrenaline may be used in patients who are moribund on presentation 
to the ED, or in an emergency situation where inhaled therapy is not 
available (evidence D).[43]
5.6 Inhaled steroids (ICS)
Insufficient evidence exists to recommend the use of ICS as alternative 
or additional therapy in acute asthma. Maintenance doses of ICS 
should be continued or started as soon as possible to form the basis 
of the chronic asthma management plan, and to allow the educational 
process regarding controller therapy to start even while the patient is 
hospitalised.[6,44-48]
5.7 Rapid-onset long-acting β2-agonists (formoterol)
Formoterol is a long-acting β2-agonist with a rapid onset of 
bronchodilation. Formoterol should never be used as monotherapy, 
as the use of long-acting β2-agonists is associated with increased risk 
of asthma mortality. Combination products containing formoterol 
and budesonide have been used as reliever medication for mild 
acute asthma symptoms in children older than 4 years (evidence 
B).49 However, there are currently insufficient data to make a 
recommendation regarding the use of formoterol as a reliever instead 
of short-acting β2-agonists in acute asthma.[50,51] 
5.8 Leukotriene receptor antagonists
There is no evidence to support the use of leukotriene receptor 
antagonists for the treatment of acute asthma in children. In three trials 
comprising 194 children with acute asthma, there was no difference 
between oral leukotriene receptor antagonists (LTRA) and controls 
(evidence A).[52] One trial in 276 children compared intravenous 
LTRA to placebo and resulted in decreased hospital admission, but 
this was not statistically significant (evidence B).[52,53] Further research 
is required regarding the role of IV LTRA in acute asthma, but there is 
currently no IV LTRA that is registered in South Africa.
5.9 Antibiotics
Antibiotics are not routinely indicated in acute asthma, which is 
usually precipitated by a viral infection (evidence D).[54]
5.10 Heliox
Current evidence does not support the use of heliox in the initial 
treatment of acute asthma, but it may have a small role in acute 
asthma in children with severe obstruction, provided hypoxaemia is 
not severe. (evidence B).[55,56]
5.11 Intravenous fluids
Patients with prolonged severe asthma may become dehydrated 
as a result of poor intake or vomiting. It is, however, inadvisable 
to overhydrate patients with acute asthma as they are prone to 
transcapillary fluid migration and alveolar flooding.[57,58]
6. Indications for hospitalisation
The indications for hospitalisation are listed in Table 5.
7. Indications for PICU admission
The indications for PICU admission are listed in Table 6. Any child 
with acute severe asthma who is not responding to maximal inhaled 
therapy and systemic steroids, or who has features of life-threatening 
asthma not responding to initial therapy, should be admitted to the 
PICU.
How to administer IV salbutamol
• Bolus dose only: 15 μg/kg in 10 ml saline over 10 minutes
• Continuous infusion: load 5 - 10 μg/kg/min of 1 mg/ml solution 
at 0.3 - 0.6 ml/kg/h for 1 hour, then salbutamol infusion 1 - 
5 μg/kg/min of a 1mg/ml solution at 0.06 - 0.3 ml/kg/h
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7.1 Treatment of acute severe asthma in ICU
The detailed management of acute severe asthma in the ICU is beyond 
the scope of this guideline, but it includes continuous nebulised 
β2-agonists with oxygen, inhaled IB added to the salbutamol, systemic 
(IV) steroids and possibly either or both IV aminophylline and IV 
salbutamol.[59,60] Non-invasive ventilation is increasingly used for the 
management of respiratory failure in acute asthma, but requires the 
patient to be co-operative.[61-63] If intubation and mechanical ventilation 
are required, the currently preferred mode of ventilation is pressure 
control or pressure support ventilation, with slower rates allowing a 
sufficiently long expiratory time to permit emptying of the lungs.[63,64] 
Ketamine is recommended for sedation in intubated patients, and 
inhaled anaesthetic gases may be required in very severe cases not 
responding to maximal other therapy.[63]
8. Acute asthma in very young children
The assessment of acute asthma in children younger than 2 years 
can be very difficult, as objective measures of severity are not always 
reliable and other conditions, such as foreign body inhalation, gastro-
oesophageal reflux with aspiration, lower respiratory tract infection, 
compression of the airways due to a congenital abnormality or 
tuberculous lymph nodes, and cystic fibrosis, may mimic asthma. 
Signs of severe acute asthma are: low oxygen saturation (SpO2 <92%), 
marked respiratory signs (using accessory muscles of respiration, 
marked retraction, tachypnoea) and inability to feed because of 
shortness of breath. Any one of these signs should place the child into 
the severe category. Apnoea, bradycardia or poor respiratory effort 
are features of life-threatening acute asthma.[6]
8.1 Treatment of acute asthma in children aged <2 years
Oxygen via close-fitting mask or nasal prongs must be administered 
to attain SpO2 >92%.
A trial of inhaled β2-agonist bronchodilator therapy should 
be instituted, in the same doses as for the older child. If there is a 
poor response to this treatment, the diagnosis of asthma should 
be reviewed. The optimal delivery system is a pMDI with spacer 
and mask for mild to moderate acute asthma, and oxygen-driven 
nebuliser for severe acute asthma (evidence A).[65-67] Oral β2-agonists 
are not recommended for the treatment of acute asthma in infants 
(evidence B). 
Oral steroids, tablets or liquid (prednisone or prednisolone) 
should be given early in the management of severe acute asthma, and 
should be continued for up to three days (evidence B).[24,68-70]
If there is a poor response to inhaled β2-agonist therapy (after 3 
treatments) or if the symptoms are more severe, add IB in the same 
dose as for older children (evidence B).[6,71]
9.  Hospital discharge and follow-up[6]
A child can be discharged when:
• he/she is stable on 3 - 4-hourly inhaled bronchodilators that can 
be continued at home
• he/she is feeding well, is not tachypnoeic and no chest wall 
indrawing is present
• SpO2 >94% in room air
• PEFR and/or FEV1 should be >75% of best or predicted
• appropriate care can be provided at home.
Caregivers and children should receive asthma education with 
the emphasis placed on treatment and inhaler technique. Children 
should be discharged on appropriate maintenance therapy with 
a spacer, educated and with a written action plan to manage 
exacerbations. They should have a follow-up appointment with their 
primary care provider within a week of discharge. Patients with 
severe exacerbations or life-threatening asthma should preferably 
be referred to a clinic with a special interest in severe asthma and 
should be discharged on ICS controller therapy. Caregivers should be 
counselled regarding environmental triggers, especially for the child 
to avoid exposure to passive smoke or indoor air pollution.
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Table 5. Indications for hospitalisation






Confusion or drowsiness 
2. Any sign of severe asthma
 Unable to complete sentences in one breath; too breathless 
to talk or feed
Agitation
Accessory muscle use
Heart rate >160 beats/min in children aged <1 year; >140
beats/min in children 1 - 5 years; >130 beats/min in children
>5 years
Respiratory rate >50 breaths/min in children aged <1 year;
>40 breaths/min in children 1 - 5 years; >30 breaths/min in
children >5 years
Room air SpO2 <92% despite bronchodilator therapy
PEFR <50% predicted
3. Moderately severe asthma not responding to β2-agonist therapy
4.  Home circumstances which do not allow safe or reliable 
treatment
Table 6. Indications for admission to PICU
Cyanosis or hypoxaemia (PaO2 <8 kPa (60 mmHg); SpO2 <90%) 
unrelieved by O2
PaCO2 >4.5 kPa (34 mmHg)
Minimal chest movement, ‘silent’ chest
Severe chest retractions
Deteriorating mental status, lethargy or agitation
Cardiorespiratory arrest
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Drug doses for acute 
asthma
β2-agonist
• pMDI with spacer: β2-agonist 2 - 10 puffs
• Give single puffs, one at a time; each 
to be inhaled separately with five tidal 
breaths at 15 - 30-second intervals
• Increase β2-agonist dose by 2 puffs 
every 2 minutes, up to 10 puffs 
according to response
• Repeat β2-agonist every 20 - 30 
minutes according to response
• Nebuliser: salbutamol 2.5 - 5 mg or 
fenoterol 0.5 - 1 mg + saline. Repeat at 
20 - 30-minute intervals
Corticosteroids
• Oral prednisone or prednisolone 1 - 2 
mg/kg (20 mg for children aged 2 - 5 
years; 30 - 40 mg for children aged >5 
years) (maximum dose 40 mg)
• IV methylprednisolone 2 mg/kg 
8-hourly
• IV dexamethasone 0.6 mg/kg daily
Ipratropium bromide (IB)
• IB 0.25 mg added to β2-agonist + saline; 
nebulise every 20 - 30 minutes x 3 doses, 
then 4 - 6-hourly
Adjunct therapies
• Single dose IV salbutamol 15 μg/kg in 10 
ml saline over 10 minutes
• Single dose IV magnesium sulphate 50% 
solution (2 mmol/ml) 0.1 ml/kg (50 mg/
kg) (maximum 2g) in 20 ml saline over 
20 minutes
Adjunct therapies in ICU
• IV salbutamol: load 5-10 μg/kg/min 
(1mg/ml solution) at 0.3-0.6ml/kg/h for 
1 hour, then salbutamol infusion 1-5 μg/
kg/min 1mg/ml solution at 0.06-0.3ml/
kg/h
• IV aminophylline load 5 mg/kg over 20 
minutes, then infuse at 0.5 -1 mg/kg/h
INITIAL ASSESSMENT: ASSESS ASTHMA SEVERITY
Brief history, vital signs, use of accessory muscles, wheezing, oxygen saturation
Grade severity according to the worst sign/symptom
Mild - moderate asthma
SpO2 >92%





Tachypnoea; using accessory muscles
PEF 33 - 50% best/predicted
Life-threatening asthma
SpO2 <92% plus any of:





ALL PATIENTS WHO PRESENT 
WITH LIFE-THREATENING 
ASTHMA MUST BE ADMITTED.
Oxygen via face mask/nasal prongs to achieve SpO2 >92%• ß2-agonist via MDI spacer 2 - 10 
   pus given singly at 15 - 30- 
   second intervals
•  oral corticosteroids •  ß2-agonist via MDI-spacer or  
    nebuliser
•  oral or IV corticosteroids
•  add nebulised ipratropium bromide
•  repeat ß2-agonist and ipratropium 
    bromide up to every 20 - 30 minutes 
    according to response
•   nebulised ß2-agonist plus nebulised 
     ipratropium bromide
•   IV corticosteroids
•   repeat nebulised ß2-agonist and  
    ipratropium bromide every 20 - 30 









Hypoxaemia despite oxygen (SpO2 <92%; 
PaO2 <8 kPa/60 mmHg)
PaCO2 >4.5 kPa/34 mmHg
Severe symptoms, drowsiness, confusion
DISCHARGE HOME
•  continue ß2-agonist via MDI-spacer 
    4-hourly as necessary
•   continue prednisone for 3 - 5 days
•   review regular treatment – inhaled 
    corticosteroids and spacer
•   written asthma action plan
•   patient education
•   follow-up primary care provider
ADMIT TO HOSPITAL WARD
•   oxygen to achieve SpO2 >92%
•   nebulised ß2-agonist plus 
    nebulised 
     ipratropium bromide
•   oral or IV corticosteroids
•   adjunct therapies: IV salbutamol 
    and/or 
    IV magnesium sulphate
ADMIT TO PICU
Monitor arterial blood gases
•   oxygen to achieve SpO2 >92%
•   continuous nebulised 
     ß2-agonist; add ipratropium 
     bromide every 20 - 30 minutes 
     till improvement then 4 - 6 
     hours
•   IV corticosteroids
•   IV magnesium sulphate if not 
     already given
•   IV salbutamol and/or IV 
     aminophylline infusions
•   non-invasive ventilation or 
     intubation and ventilation 
Improve
Improve
NB: ß2-agonist = short acting ß2-agonist 
See text box for drug doses
Management of acute severe asthma in children
